文献速递淋巴瘤

抗原结合和信号传导受损影响双特异性CD19和CD79a嵌合抗原受体功能

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function.
PubMed 文献 · Blood Adv · 2023-01-01

研究探讨靶向CD19和CD79a/b的双特异性CAR-T细胞能否克服抗原逃逸。免疫组化显示84.3%淋巴瘤表达CD79a/b,其中87.3%共表达CD19。双特异性CAR-T可防止CD19丢失淋巴瘤异种移植模型中抗原阴性细胞生长,但串联和双顺反子CAR-T对仅表达单一抗原的肿瘤效果不及单特异性CAR-T,并分别存在抗原结合减少和下游信号磷酸化降低的缺陷。

要点

  • 84.3%淋巴瘤病例免疫组化表达CD79a/b,其中87.3%共表达CD19。
  • 双特异性CAR-T可防止CD19丢失淋巴瘤异种移植模型中抗原阴性细胞生长。
  • 串联和双顺反子CAR-T对仅表达CD19或CD79的肿瘤效果不及相应单特异性CAR-T。

核心结论

  • 尽管增加了特异性,串联和双顺反子CAR-T细胞表现出不同缺陷,损害对表达单一抗原肿瘤细胞的识别。
  • 数据支持靶向多种B细胞抗原以提高疗效,并识别双特异性受体设计需改进之处。

研究设计与样本

  • 研究构建了串联、双顺反子和混合产物三种CD79a-CD19或CD79b-CD19双特异性CAR-T细胞。
  • 使用CD19丢失淋巴瘤异种移植模型评估双特异性CAR-T对抗原阴性细胞生长的作用。
  • 比较双特异性与单特异性CD19或CD79a CAR-T对仅表达相应单一抗原肿瘤的治疗效果。
  • 采用免疫组化检测淋巴瘤病例中CD79a/b和CD19的表达。

主要发现

  • 免疫组化显示84.3%的淋巴瘤病例表达CD79a/b,87.3%的CD79ab阳性肿瘤共表达CD19。
  • 双特异性CAR-T细胞 prevented 抗原阴性细胞在CD19丢失淋巴瘤异种移植模型中的生长。
  • 串联和双顺反子CAR-T细胞对仅表达CD19或CD79的肿瘤效果不及单特异性CD19或CD79a CAR-T细胞。
  • 与单特异性CAR-T细胞相比,表达串联CAR的T细胞对每种靶抗原的结合减少。
  • 与单特异性CAR-T细胞相比,表达双顺反子CAR载体的T细胞下游CAR信号分子磷酸化减少。

关键数值与推荐

  • 84.3%淋巴瘤病例免疫组化表达CD79a/b。
  • 87.3%的CD79ab阳性肿瘤共表达CD19。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy with CD19-directed chimeric antigen receptor (CAR) T cells has transformed the treatment of advanced B-cell malignancies. However, loss of or low antigen expression can enable tumor escape and limit the duration of responses achieved with CAR T-cell therapy. Engineering bispecific CAR T cells that target 2 tumor antigens could overcome antigen-negative escape. We found that CD79a and b, which are heterodimeric components of the B-cell receptor, were expressed on 84.3% of lymphoma cases using immunohistochemistry, and 87.3% of CD79ab-positive tumors also coexpressed CD19. We generated 3 bispecific permutations: tandem, bicistronic, and pooled products of CD79a-CD19 or CD79b-CD19 CAR T cells and showed that bispecific CAR T cells prevented the outgrowth of antigen-negative cells in a CD19-loss lymphoma xenograft model. However, tandem and bicistronic CAR T cells were less effective than monospecific CD19 or CD79a CAR T cells for the treatment of tumors that only expressed CD19 or CD79, respectively. When compared with monospecific CAR T cells, T cells expressing a tandem CAR exhibited reduced binding of each target antigen, and T cells expressing a bicistronic CAR vector exhibited reduced phosphorylation of downstream CAR signaling molecules. Our study showed that despite added specificity, tandem and bicistronic CAR T cells exhibit different defects that impair recognition of tumor cells expressing a single antigen. Our data provide support for targeting multiple B-cell antigens to improve efficacy and identify areas for improvement in bispecific receptor designs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Leung I, Templeton ML, Lo Y, et al. Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. Blood Adv. 2023. PMID: 36469024. doi:10.1182/bloodadvances.2022008559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。